- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.03. | Lobe Sciences Ltd. meldet verbesserte Finanzlage und gibt strategisches Update bekannt | 303 | IR-WORLD | - Verbindlichkeiten um 81 % reduziert, von 2,35 Mio. $ auf 0,44 Mio. $
- Barmittel um mehr als das 24-Fache gestiegen, von 0,24 Mio. $ auf 5,99 Mio. $
... ► Artikel lesen | |
| 25.03. | Lobe Sciences Ltd. Reports Improved Financial Position and Strategic Update | 218 | ACCESS Newswire | Liabilities reduced 81%, from $2.35M to $0.44MCash increased more than 24x, from $0.24M to $5.99MNet working capital improved by $6.1M, from ($2.01M) to $4.05MOutstanding warrants reduced by ~70%, from... ► Artikel lesen | |
| 09.03. | Lobe Sciences names Mirza Rahimani as CFO; succeeds Yong Yao | 1 | Seeking Alpha | ||
| 09.03. | Lobe Sciences Ltd.: Lobe Sciences Announces Appointment of Mr. Mirza Rahimani, CPA, CA as Chief Financial Officer | 387 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / March 9, 2026 / Lobe Sciences Ltd. (Lobe) (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE) is a Canadian public biopharmaceutical company incorporated in British Columbia, with... ► Artikel lesen | |
| 05.03. | Lobe Sciences Ltd. Announces Presence in Miami During the Jefferies and Leerink Healthcare Conferences | 192 | ACCESS Newswire | VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / March 5, 2026 / Lobe Sciences Ltd. (Lobe) (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE) is a Canadian public biopharmaceutical company incorporated in British... ► Artikel lesen | |
| 03.02. | Lobe Sciences Ltd (2): Lobe Sciences' Nov. 30 cash at $5.99-million | 1 | Stockwatch | ||
| 03.02. | Lobe Sciences Ltd.: Lobe Sciences Reports First Quarter 2026 Results and Highlights | 351 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / February 3, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in diseases... ► Artikel lesen | |
| LOBE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 13.01. | Lobe Sciences Ltd (2): Lobe Sciences appoints Karakochuk as director | 1 | Stockwatch | ||
| 13.01. | Lobe Sciences Ltd.: Lobe Sciences Advances Governance and Capital Markets Expertise with Appointment of Mr. Nick Karakochuk to the Board of Directors | 338 | ACCESS Newswire | VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 13, 2026 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| 09.01. | Lobe Sciences Ltd (2): Lobe Sciences ends FY 2025 with cash of $5.85-million | 1 | Stockwatch | ||
| 08.01. | Lobe Sciences Ltd.: Lobe Sciences Reports FY2025 with a Stronger Balance Sheet and Sharpened Strategy | 259 | ACCESS Newswire | Balance Sheet and Sharpened Strategy VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 8, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical... ► Artikel lesen | |
| 06.01. | Lobe Sciences Ltd (2): Lobe Sciences has cash of $5.85-million at Aug. 31 | 1 | Stockwatch | ||
| 06.01. | Lobe Sciences Ltd.: Lobe Sciences Reports Fiscal 2025 Results and Highlights Strategic Transformation Following Leadership Transition | 341 | ACCESS Newswire | VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 6, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in... ► Artikel lesen | |
| 24.10.25 | Lobe Sciences Ltd.: Lobe Sciences Completes Debt Settlement to Improve Balance Sheet | 370 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / October 23, 2025 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), operates as a pharmaceutical platform that develops novel therapies... ► Artikel lesen | |
| 09.10.25 | Lobe Sciences Ltd.: Lobe Sciences Improves Balance Sheet | 312 | ACCESS Newswire | VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / October 9, 2025 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), operates as a pharmaceutical platform that develops... ► Artikel lesen | |
| 16.09.25 | ArcStone US Corp.: Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto | 700 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - September 15, 2025) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (FSE: LOBE.F) ("Lobe Sciences" or the "Company") a clinical stage biopharmaceutical... ► Artikel lesen | |
| 10.09.25 | Lobe Sciences Ltd. and Cynaptec Pharmaceuticals, Inc. to Present a New Therapeutic Approach for the Treatment of Chronic Cluster Headaches at Clusterbusters 2025 | 522 | ACCESS Newswire | VANCOUVER, B.C. / ACCESS Newswire / September 9, 2025 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) a clinical stage biopharmaceutical company focused on developing... ► Artikel lesen | |
| 09.09.25 | Lobe Sciences Ltd.: Lobe Sciences Announces the Appointment of Marco Mastrodonato to its Board of Directors | 516 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / September 8, 2025 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) a clinical stage biopharmaceutical company focused on... ► Artikel lesen | |
| 15.08.25 | Lobe Sciences Ltd.: Lobe Sciences Announces the Closing of the Previously Announced Private Placement | 526 | ACCESS Newswire | NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / August 14, 2025 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company")... ► Artikel lesen | |
| 29.07.25 | Lobe Sciences Ltd. Engages ArcStone Securities for Strategic Capital Markets Advisory | 566 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / July 29, 2025 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a biopharmaceutical company focused on developing therapeutics for rare and underserved diseases... ► Artikel lesen |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONXT SOLUTIONS | 0,316 | +0,32 % | BioNxt sichert sich einheitliches europäisches Patent für seine sublinguale Cladribin-ODF-Plattform in 18 Ländern | VANCOUVER, BC / ACCESS Newswire / 7. April 2026 / BioNxt Solutions Inc. ("BioNxt" oder das "Unternehmen") (CSE:BNXT)(OTCQB:BNXTF)(FWB:BXT), ein innovatives Biowissenschaftsunternehmen, das
sich... ► Artikel lesen | |
| ATAIBECKLEY | 3,220 | +1,90 % | Depression und PTBS im Fokus: Wie Emyria und AtaiBeckley neue Wirtschaftsmodelle in der Psychiatrie prägen | ||
| SOL GLOBAL INVESTMENTS | 0,026 | +4,00 % | XFRA 9SB0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSOL GLOBAL INVESTM.... ► Artikel lesen | |
| ENTHEON BIOMEDICAL CORP | 0,040 | 0,00 % | Entheon Biomedical Corp.: Entheon Announces Execution of Business Combination Agreement with Nutravisor | Toronto, Ontario--(Newsfile Corp. - January 19, 2026) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") is pleased to announce that it has entered into... ► Artikel lesen | |
| CYBIN | 4,395 | -2,01 % | Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer | Proven human resources and organizational strategist brings more than two decades of leadership across the pharmaceutical industryAppointment supports Helus Pharma's continued maturation as the company... ► Artikel lesen | |
| REVIVE THERAPEUTICS | 0,015 | 0,00 % | Revive Therapeutics Ltd.: Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases | Patent momentum expands Revive's bucillamine franchise across medical countermeasures, infectious diseases and additional high-value strategic applications TORONTO, ON / ACCESS Newswire / March 11,... ► Artikel lesen | |
| RAPID DOSE THERAPEUTICS | - | - | Rapid Dose Therapeutics Corp.: Rapid Dose Announces Payment in Shares for Quarterly Interest on Secured Debt | Burlington, Ontario--(Newsfile Corp. - April 6, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company") announced today that pursuant to the terms of its amended... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 86,52 | 0,00 % | Morning Market Movers: urban-gro, WeShop Holdings, QVC Group, Apogee Therapeutics See Big Swings | OTTAWA (dpa-AFX) - At 8:30 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ARCELLX | 114,80 | +0,01 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 18,050 | 0,00 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates | Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated... ► Artikel lesen | |
| ONCONETIX | 1,210 | 0,00 % | Onconetix, Inc.: Onconetix Highlights Realbotix's Launch of Vinci AI Vision System with Delivery of First Vinci-Equipped Humanoid Robot to Ericsson | ||
| AMYLYX PHARMACEUTICALS | 17,320 | 0,00 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 33,520 | 0,00 % | Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs | - CIRRUS-HCM 12-week data of EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) expected in H1 2026 -
- Phase 1 healthy adult trial... ► Artikel lesen | |
| BICARA THERAPEUTICS | 21,980 | 0,00 % | Bicara Therapeutics Inc.: Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) | ||
| ENLIVEN THERAPEUTICS | 45,620 | 0,00 % | H.C. Wainwright reiterates Enliven Therapeutics stock rating on Terns deal details |
LOBE SCIENCES LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +23,53 % bei einem Aktienkurs von 0,042 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LOBE SCIENCES LTD finden Sie auf Wallstreet Online.